Normal view

Received — 14 March 2026 ⏭

Nature Medicine
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis Stephan A. Kaeser · Stephanie A. Schultz · Anna Hofmann · Lisa M. Häsler · Ying Xu · Marius Lambert · Ulrike Obermüller · Kathrin Brockmann · Johan Bijzet · Hans Nienhuis · Mario Nuvolone · Laura Obici · Giovanni Palladini · Ute Hegenbart · Stefan O. Schönland · Mathias Jucker
Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.
11 March 2026 at 08:00

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

By: Stephan A. Kaeser · Stephanie A. Schultz · Anna Hofmann · Lisa M. Häsler · Ying Xu · Marius Lambert · Ulrike Obermüller · Kathrin Brockmann · Johan Bijzet · Hans Nienhuis · Mario Nuvolone · Laura Obici · Giovanni Palladini · Ute Hegenbart · Stefan O. Schönland · Mathias Jucker

11 March 2026 at 08:00

Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2

Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.